As such, ONX-0914, the most studied ImP inhibitor, blocks PSMB8 and has been reported to induce cell death in pre-clinical models of glioblastoma, acute lymphoblastic leukemia, NSCLC, colorectal, gastric and castration-resistant prostate cancers (55, 107, 120–125). This evidence concerns the gene PSMB8 and non-small cell lung carcinoma.